• Admedus to enter new revenue vertical with vascular product to be launched in November 2016
• Vascular repair market worth circa USD$500 million per annum
• Manufacturing and supply facilities implemented and ready for product launch
• Cardiocel® brand awareness and established relationships to assist with marketing and penetration of the vascular product
• Recently received 8 year Cardiocel® data confirms lack of calcification and remodeling capabilities giving patients and surgeons both near and longer-term benefits in repairing vascular defects
Brisbane, Australia 25 August 2016
Admedus Limited (ASX: AHZ) today announced that the manufacturing team have met the internal timeline of being prepared for the manufacture of VascuCel® for the November launch date.
“We are very excited to be able to add products to the portfolio which provide much needed alternatives to surgeons and patients in the vascular repair space” stated Mr Wayne Paterson, Chair and Interim CEO.
After months of intense review and implementation of manufacturing systems, the Malaga factory will be ready to supply VascuCel alongside its current output of CardioCel® by November 1st, 2016.
VascuCel is an exciting new product for use in repair of vascular surgical procedures such as carotid endarterectomy (CEA), coronary revascularisation, vascular aneurism repairs and other vascular repairs, addressing a market worth in excess of USD$500 million per annum. In the US market there are over 170,000 CEA procedures performed each year and many more globally.
The VascuCel product will have the characteristics and patient benefits of the ADAPT tissue as experienced with CardioCel, such as the lack of calcification recently reported for CardioCel after over 8 year post implantation. Data also shows ADAPT tissue has unique remodelling properties giving patients and surgeons both near and longer-term benefits in repairing vascular defects.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus
Website: www.admedus.com
Blog: www.admedus.com/au/category/news/
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 (0)8 9266 0100
Media:
Shevaun Cooper | PR Manager | Admedus Limited
Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com
Media Europe
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
admedus@fticonsulting.com
US Investor
Rx Communications Group, LLC
Melody A. Carey
+1 917 322 2571
mcarey@rxir.com
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
